+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years - 75Years
All Genders
ID07083960

Open-Label Study Evaluating Multiple Ascending Doses of OM336 via Subcutaneous Injection in Adults With Active Autoimmune Cytopenias

Led by Lakefront Biotherapeutics West LLC · Updated on 2026-09-03

32

Participants Needed

7

Research Sites

39 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating OM336, an engineered bispecific antibody targeting BCMA and CD3, in adult participants with active autoimmune cytopenias, including warm and cold autoimmune hemolytic anemia and immune thrombocytopenia. This early-phase, open-label, multicenter study focuses on assessing the safety, tolerability, and pharmacokinetics of OM336 administered subcutaneously in ascending dose cohorts. Participants will receive OM336 through subcutaneous injections in increasing doses to evaluate its effects. The study includes multiple dose escalation groups to monitor how participants respond to the treatment over time. The primary treatment period lasts 12 weeks, with additional safety and tolerability assessments extending to 52 weeks to closely observe longer-term effects. During the study, participants will be monitored for safety and tolerability through regular assessments, including pharmacokinetic measurements and tests for anti-drug antibodies. The research team will track participant responses over the course of treatment and follow-up visits. The total participation may last up to 52 weeks, allowing detailed evaluation of both immediate and sustained effects of OM336.

CONDITIONS

Brief Title

OM336 in Autoimmune Cytopenias

Research Team

S

Study Sponsor

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here